



Perspectives of Immunotherapy in Tumors of the Gastrointestinal Tract

Guest Editor:

Dr. Gianluca Masi

Department of Translational
Research and New Technologies
in Medicine, Unit of Medical
Oncology, Azienda Ospedaliero-
Universitaria Pisana, University of
Pisa, 56121 Pisa, Italy

Deadline for manuscript
submissions:

closed (20 August 2022)

Message from the Guest Editor

Dear Colleagues,

The use of immune-based therapies such as immune checkpoint inhibitors (ICIs) has become a standard therapy in various cancer types. The therapeutic application of monoclonal antibodies targeting inhibitory pathways such as programmed cell death-1(PD-1)/programmed cell death ligand 1 (PD-L1) and CTLA-4 has recently been shown to generate meaningful improvements in clinical outcomes, as well as in cancers of the gastrointestinal tract (mainly esophageal and gastric cancer, and colorectal cancer with microsatellite instability).

We welcome submissions of research and review articles on the molecular mechanisms that contribute to the response to immune-based therapies in cancer of the gastrointestinal tract to bring together expert opinions and new advances from across the field in a Special Issue of *Cancers*. We welcome submissions that cover any relevant topic, including the role of immunotherapy, potential predictive factors, the role of gut microbiota, and new therapeutic opportunities including new drug combinations.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI